To access this material please log in or register

Register Authorize

The issue of anemic syndrome in CHF: a review of results from the RED-HF study and own data

Abdullaev T. A., Tsoy I. A.
Republican Specialized Center of Cardiology, Osiyo 4, Tashkent 100052, Republic of Uzbekistan

Keywords: anemia, recombinant erythropoietin, CHF

DOI: 10.18087/rhfj.2015.6.2149

We attempted to perform a critical analysis of the RED HF study, the results of which allowed a conclusion that the treatment of CHF patients with recombinant erythropoietin (rEPO) is unsafe. Results of own observations are presented.
  1. Stewart S, Macintyre K, Hole DJ, Capewell S, McMurray JJ. More «malignant» than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001 Jun;3 (3):315–22.
  2. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003 Jun 4;41 (11):1933–9.
  3. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004 Jul 13;110 (2):149–54.
  4. He SW, Wang LX. The impact of anemia on the prognosis of chro­nic heart failure: a meta-analysis and systemic review. Congest Heart Fail. 2009 May-Jun;15 (3):123–30.
  5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. 2013 ACCF / AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62 (16):e147–239.
  6. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct;10 (10):933–89.
  7. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heartfailure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008 Sep 2;52 (10):818–27.
  8. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 Aug;31 (15):1872–80.
  9. Meneveau N, Schiele F, Seronde MF, Descotes-Genon V, Oettinger J, Chopard R et al. Anemia for risk assessment of patients with acute coronary syndromes. Am J Cardiol. 2009 Feb 15;103 (4):442–7.
  10. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a rando­mized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008 Jan 15;51 (2):103–12.
  11. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361 (25):2436–48.
  12. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015 Mar 14;36 (11):657–68.
  13. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003 Jan 21;107 (2):294–9.
  14. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G et al. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003 Jan;18 (1):141–6.
  15. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006 Dec;152 (6):1096.e9–15.
  16. Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev. 2010 Jan 20; (1):CD007613.
  17. Van der Meer P, Lipsic E, van Gilst WH, van Veldhuisen DJ. Anemia and erythropoietin in heart failure. Heart Fail Monit. 2008;6 (1):28–33.
  18. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008 Jan 29;117 (4):526–35.
  19. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of anemia with darbepotin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28;368 (13):1210–9.
  20. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  21. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014 Oct;11 (5):532–46.
  22. Фонякин А. В., Гераскина Л. А. Профилактика ишемического инсульта. Рекомендации по антитромботической терапии. – М.: ИМА-ПРЕСС, 2014. – 72с.
  23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137 (2):263–72.
  24. Агеев Ф. Т., Арутюнов Г. П., Беленков Ю. Н., Васюк Ю. А., Мареев В. Ю., Мартыненко А. В. и др. Хроническая сердечная недостаточность. – М.: «ГЭОТАР-Медиа», 2010. – С. 7–77.
  25. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 Jul 11;154 (13):1449–57.
  26. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987 Jun 4;316 (23):1429–35.
  27. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991 Aug 1;325 (5):293–302.
  28. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325 (5):303–10.
  29. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM et al. Comparative effects of low doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Circulation. 1999 Dec 7;100 (23):2312–8.
  30. Schindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus: a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996 May 1;77 (11):1017–20.
  31. Clark CM Jr, Perry RC. Type 2 diabetes and macro vascular disease: epidemiology and etiology. Am Heart J. 1999 Nov;138 (5 Pt 1):S330–3.
  32. Brott T, Broderrick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997 Jan;28 (1):1–5.
  33. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014 Dec 16;64 (23):2471–82.
Abdullaev T. A., Tsoy I. A. The issue of anemic syndrome in CHF: a review of results from the RED-HF study and own data. Russian Heart Failure Journal. 2015;16 (6):379–383

To access this material please log in or register

Register Authorize
Ru En